A study in the journal Science Advances found that the green, bile-tinted blood of lizards in the genus Prasinohaema is toxic to malaria parasites in laboratory tests. Researchers believe the trait developed independently in six species of lizards on the island of New Guinea.
Sen. Richard Burr, R-N.C., has introduced a bipartisan bill to update the Pandemic and All-Hazards Preparedness Act, or PAHPA, several provisions of which would build on the current PAHPA framework that was enacted in 2006 and reauthorized in 2013. One provision would re-evaluate preparedness and response of the Hospital Preparedness Program and Public Health Emergency Preparedness Program in terms of existing performance measures, benchmarks and standards.
GeneNews and St. Louis-based reference laboratory AIM Laboratories have reached an agreement to provide each other's customer base access to their tests for undisclosed terms. GeneNews makes tests for facilitating early cancer risk stratification and diagnosis, while AIM offers therapeutic drug monitoring, routine blood testing and other lab services to corporate and health care groups.
In a study of people with HIV, more frequent use of methamphetamine was found to be associated with changes in gene expression and a 50% increased risk of disease progression, according to a study in the journal Brain, Behavior, and Immunity. The findings were based on an analysis of gene expression in 55 people.
Two French gene therapy companies, Vectalys and FlashCell, are merging under the name Flash Therapeutics. Discovery and development of therapies for blood and liver diseases will continue.
The first experimental Ebola vaccines from the World Health Organization have arrived in the Democratic Republic of Congo, and the country will begin inoculations this weekend. Meanwhile, Public Health Minister Oly Ilunga Kalenga said an Ebola case had been found in Mbandaka, a city of about 1 million.
The Cherokee Nation began a hepatitis C prevention program three years ago with the goal of screening 80,000 of its 350,000 members, and over 50% of the target group has been screened, while 90% of people with detected cases who have received care have responded to treatment. John Ward of the CDC said the program is "a trailblazing project for the entire country."
Roche will present data from its late-stage HAVEN 3 and HAVEN 4 clinical trials evaluating its candidate Hemlibra, or emicizumab, on May 21 at the World Federation of Hemophilia 2018 World Congress in Scotland. The data include positive results showing the efficacy of Hemlibra in hemophilia A patients without factor VIII inhibitors dosed once weekly or every other week in the HAVEN 3 study and of doses given every four weeks for hemophilia A patients with or without factor VIII inhibitors in the HAVEN 4 trial.
The FDA has given final approval for Eagle Pharmaceuticals' ready-to-dilute bendamustine hydrochloride solution in a 500ml admixture, an injection that requires no reconstitution, to treat patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.